Spike–Wave Discharges and Sleep–Wake States during Circadian Desynchronization: No Effects of AGOMELATINE (cas 138112-76-2) upon Re-Entrainment

Add time:08/21/2019    Source:sciencedirect.com

Rapid changes in the light–dark cycle cause circadian desynchronization between rhythms of spike–wave discharges (SWDs) and motor activity in genetic epileptic rats, and this is accompanied by an increase in epileptic activity. Given the close relationship between absence seizures and sleep–wake states, the present study assessed firstly a putative relationship between vigilance rhythms and SWDs during re-synchronization, and secondly sleep–wake patterns responsible for increased epileptic activity. Lastly, in a view of existing evidence that melatonin and its agonists accelerate re-synchronization, the effects of different doses of AGOMELATINE (cas 138112-76-2) upon the speed of re-synchronization of different sleep–wake states and SWDs were investigated.Simultaneous electroencephalographic and electromyographic recordings were made in symptomatic WAG/Rij rats, before, during and 10 days following an 8 h light phase delay. Agomelatine was orally administered acutely and sub-chronically, during 10 post-shift days.The magnitude of the advance after the shift and the speed of re-synchronization were specific for various rhythms. Most prominent change was the increase in REM sleep duration during the dark phase. A post-shift increase in passive wakefulness and a reduction in deep slow-wave sleep coincided with an aggravation of SWDs during the light phase. Agomelatine showed neither an effect on sleep–wake parameters and SWDs, nor affected re-synchronization.The same speed of re-synchronization of SWDs and light slow-wave sleep suggests that both are controlled by a common circadian mechanism. The redistribution of SWDs and their increase in the light phase after the shift may be of importance for patients with absence epilepsy planning long trans-meridian flight across time zones.

We also recommend Trading Suppliers and Manufacturers of AGOMELATINE (cas 138112-76-2). Pls Click Website Link as below: cas 138112-76-2 suppliers

Prev:AGOMELATINE (cas 138112-76-2)-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus
Next:Research paperEffect of AGOMELATINE (cas 138112-76-2) 25–50 mg on functional outcomes in patients with major depressive disorder)